Prospera Financial Services Inc Cardiff Oncology, Inc. Transaction History

Prospera Financial Services Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$1.17 - $2.61 $4,779 - $10,661	-4,085 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$2.11 - $7.25 $8,619 - $29,616	4,085 New	4,085 $10,000
Q2 2021 Aug 12, 2021	SELL	$6.65 - $10.04 $177,222 - $267,566	-26,650 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$9.1 - $19.57 $178,669 - $384,237	-19,634 Reduced 42.42%	26,650 $247,000
Q4 2020 Feb 12, 2021	BUY	$12.02 - $24.71 $556,333 - $1.14 Million	46,284 New	46,284 $833,000
Q3 2020 Nov 04, 2020	SELL	$4.25 - $14.19 $409,700 - $1.37 Million	-96,400 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$0.78 - $5.1 $75,192 - $491,639	96,400 New	96,400 $483,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

Stay updated on Prospera Financial Services Inc with notifications on news.